U.S. stock market update: Vor BioPharma down 7.56%

U.S. Stock Market Midday Update

Vor BioPharma fell 7.56%, with increased trading volume. Based on recent important news:

1. On June 26, Rongchang Biologics announced a licensing agreement with Vor Bio, granting Vor Bio global development rights for Taitasip, but the market reacted lukewarmly, causing Vor Bio's stock price to drop.

2. On June 26, Vor Bio laid off 95% of its staff due to product development setbacks, raising doubts about its commercialization capabilities, which affected its stock price.

3. On July 1, Vor Bio reported the granting of inducement stock options under Nasdaq rules, failing to boost market confidence.

Stocks with High Trading Volume in the Industry

Sarepta Therapeutics fell 37.55%, with increased trading volume. Based on recent important news:

1. On July 17, Sarepta announced a 36% workforce reduction and plans to save $400 million by 2026. This news led to a 33% increase in stock price after hours.

2. On July 17, the FDA required a black box warning for Elevidys due to the deaths of two patients. This raised market concerns about its safety.

3. On July 18, the death of a third patient caused a significant drop in stock price, nearly erasing the gains from the restructuring.

CRISPR Therapeutics rose 15.63%, with increased trading volume. Based on recent important news:

1. On July 18, CRISPR Therapeutics board member Simeon George purchased $51.5 million in stock, leading to a 21% surge in stock price.

2. On July 17, analysts projected the company's sales to approach $200 million next year, driving the stock price up.

3. On July 17, the gene editing drug market is expected to grow at an average annual rate of 13%, which is favorable for the company's outlook.

MEI Pharma rose 32.56%, with a trading volume of $297 million. Based on recent important news:

1. On July 18, MEI Pharma announced a $100 million private placement plan, using Litecoin as a treasury reserve asset, resulting in a 108.67% increase in stock price.

2. On July 18, Litecoin founder Charlie Lee joined the board, boosting market confidence.

3. On July 18, GSR became a digital asset and treasury management advisor, driving the stock price up.

Stocks with High Market Capitalization in the Industry

AbbVie fell 1.38%, with increased trading volume. Based on recent important news:

1. On July 17, there was an order imbalance on the New York Stock Exchange, with 566,742 shares on the buy side for AbbVie, leading to a 1.38% drop in stock price.

2. On July 16, analysts gave AbbVie an "overweight" rating with a target price of $214.13, failing to boost market confidence.

3. On July 17, AbbVie's competitive position in the migraine treatment market did not significantly improve, and the market reacted lukewarmly